Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases

被引：3
作者：
Hingorani, Mohan [1 ]
Dixit, Sanjay [1 ]
Pugazhenthi, Pattu [1 ]
Hawkyard, Simon [2 ]
Robertson, Andrew [2 ]
Khafagy, Richard [2 ]
机构：
[1] NHS Trust, Castle Hill Hosp, Dept Clin Oncol, Cottingham HU16 5JQ, East Riding Yor, England
[2] Scarborough Dist Gen Hosp, Dept Urol, Scarborough M1P 2V5, ON, Canada
来源：
CANCER BIOLOGY & MEDICINE | 2015年 / 12卷 / 01期
关键词：
Chemotherapy; Palliative; Prostate cancer; Radiotherapy;
D O I：
10.7497/j.issn.2095-3941.2014.0025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and abiraterone (n=1), who responded unusually after pRT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy. The possibility of pRT influencing metastatic disease in CRPC has not been previously reported, and raises the possibility of radiation-induced modulation of anti-tumor immune response mechanisms that may play a role in the restoration of response to systemic treatment.
引用
收藏
页码：60 / 63
页数：4
相关论文
共 50 条
  • [41] Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
    Belli, Maria Luisa
    Sarnelli, Anna
    Mezzenga, Emilio
    Cesarini, Francesco
    Caroli, Paola
    Di Iorio, Valentina
    Strigari, Lidia
    Cremonesi, Marta
    Romeo, Antonino
    Nicolini, Silvia
    Matteucci, Federica
    Severi, Stefano
    Paganelli, Giovanni
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [42] Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen-Deprivation Therapy
    Choueiri, Toni K.
    Xie, Wanling
    D'Amico, Anthony V.
    Ross, Robert W.
    Hu, Jim C.
    Pomerantz, Mark
    Taplin, Mary-Ellen
    Kantoff, Philip W.
    Sartor, Oliver
    Oh, William K.
    CANCER, 2009, 115 (05) : 981 - 987
  • [43] Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy
    Lernbessis, Peter
    Msaouel, Pavlos
    Halapas, Antonis
    Sourla, Antigone
    Panteleakou, Zacharoula
    Pissimissis, Nikolaos
    Milathianakis, Constantine
    Bogdanos, John
    Papaioannou, Andreas
    Maragoudakis, Evangelos
    Dardoufas, Constantine
    Dimopoulos, Theodoros
    Koutsilieris, Michael
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (11) : 1488 - 1494
  • [44] Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302
    Martin, Lisa J.
    Alibhai, Shabbir M. H.
    Komisarenko, Maria
    Timilshina, Narhari
    Finelli, Antonio
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (06): : 192 - 200
  • [45] Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naive, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide
    Miyake, Hideaki
    Hara, Takuto
    Tamura, Keita
    Sugiyama, Takayuki
    Furuse, Hiroshi
    Ozono, Seiichiro
    Fujisawa, Masato
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (06) : 432 - 437
  • [46] The Safety and Efficacy of Targeted Alpha Therapy, Ac-225 Prostate-Specific Membrane Antigen, in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Besiroglu, Huseyin
    Kadihasanoglu, Mustafa
    PROSTATE, 2025, : 541 - 557
  • [47] The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score
    Miller, Kurt
    Carles, Joan
    Gschwend, Juergen E.
    Van Poppel, Hendrik
    Diels, Joris
    Brookman-May, Sabine D.
    EUROPEAN UROLOGY, 2018, 74 (01) : 17 - 23
  • [48] Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
    Salgaller, ML
    Lodge, PA
    McLean, JG
    Tjoa, BA
    Loftus, DJ
    Ragde, H
    Kenny, GM
    Rogers, M
    Boynton, AL
    Murphy, GP
    PROSTATE, 1998, 35 (02) : 144 - 151
  • [49] Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium
    Tohi, Yoichiro
    Kato, Takuma
    Kobayashi, Keita
    Daizumoto, Kei
    Fukuhara, Hideo
    Ohira, Shin
    Katayama, Satoshi
    Shimizu, Ryutaro
    Takamoto, Atsushi
    Nishimura, Kenichi
    Ikeda, Kenichiro
    Nagami, Taichi
    Hayashida, Yushi
    Hirama, Hiromi
    Naito, Hirohito
    Tomida, Ryotaro
    Sasaki, Yutaro
    Yamamoto, Shinkuro
    Shimizu, Shinjiro
    Sugimoto, Mikio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (02) : 167 - 174
  • [50] Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy: Is it possible to identify patients likely to have good treatment outcomes?
    Kurokawa, K
    Ito, K
    Suzuki, K
    Ono, Y
    Yamamoto, T
    Akimoto, T
    Yamanaka, H
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (11) : 466 - 471
12345